Market Place
Sourcing Support
Appointment Of Marc Le Bozec As Interim CEO
03 Oct 2025 //
GLOBENEWSWIRE
Board Of Directors Fully Renewed; Dr. Markus Cappel Re-Elected
30 Sep 2025 //
GLOBENEWSWIRE
OSE Immuno, Inserm, Nantes University Form Partnership
26 Sep 2025 //
GLOBENEWSWIRE
Correction Of Voting Rights And Shares Comprising Share Capital
24 Sep 2025 //
GLOBENEWSWIRE
International Proxy Advisory Firms Back Ose Immunotherapeutics`
22 Sep 2025 //
GLOBENEWSWIRE
General Meeting Update for September 30, 2025
12 Sep 2025 //
GLOBENEWSWIRE
OSE, FoRT Complete Enrollment of Ph 2 Tedopi+Nivolumab NSCLC
11 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Urges Support for Strategy and Governance
09 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Updates on Proceedings Before Sept 30
08 Sep 2025 //
GLOBENEWSWIRE
Ose Immunotherapeutics Strengthens Strategy and Governance
04 Sep 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reaffirms Strategic Priorities, Shares
29 Aug 2025 //
GLOBENEWSWIRE
OSE Immuno Proposes Governance Changes, Reaffirms Strategy
25 Aug 2025 //
GLOBENEWSWIRE
Thomas Gidoin Named CFO at OSE Immunotherapeutics
20 Aug 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Launches Newsletter for Retail Investors
17 Jul 2025 //
GLOBENEWSWIRE
Half-Year Liquidity Contract Report with Invest Securities
16 Jul 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics updates information on ongoing procedures
02 Jul 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Publishes Letter to Shareholders
30 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics provides an update on ongoing proceedings
25 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reaffirms Transparent General Meeting
20 Jun 2025 //
GLOBENEWSWIRE
General meeting adjourned from June 25, 2025
11 Jun 2025 //
GLOBENEWSWIRE
Update on The Terms of The Shareholders General Meeting
09 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Accelerates Strategy in Inflammation
04 Jun 2025 //
GLOBENEWSWIRE
Ose Immunotherapeutics: Shareholder documents for June 25, 2025
04 Jun 2025 //
GLOBENEWSWIRE
OSE Immuno Updates on Tedopi in Pancreatic and Lung Cancer
02 Jun 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics & Boehringer Ingelheim to Present Clinical
23 May 2025 //
GLOBENEWSWIRE
OSE to lead mRNA project with €1.3M from French government
21 May 2025 //
FIERCE BIOTECH
OSE Immuno: 90% Stay in Remission with Lusvertikimab Extension
05 May 2025 //
GLOBENEWSWIRE
Immuno-Oncology Results Presented at AACR Annual Meeting 2025
30 Apr 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Abstracts Selected for ASCO 2025
23 Apr 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports 2024 Financial Results
26 Mar 2025 //
GLOBENEWSWIRE
Ose Immune Report Positive Ph II TEDOPaM Trial In Pancreatic Cancer
11 Mar 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics Hosts KOL Webinar on Lusvertikimab and IBD
06 Mar 2025 //
GLOBENEWSWIRE
OSE Immuno Reports Full Ph 2 Lusvertikimab Data In Ulcerative Colitis
24 Feb 2025 //
GLOBENEWSWIRE
OSE Immuno Presents Preclinical Lusvertikimab Data In Chronic Colitis
20 Feb 2025 //
GLOBENEWSWIRE
OSE Immuno, Scienta Lab Partner To Leverage AI In Immunotherapy
29 Jan 2025 //
GLOBENEWSWIRE
OSE Immuno Presents Anti-IL-7R Lusvertikimab In Ulcerative Colitis
28 Jan 2025 //
GLOBENEWSWIRE
OSE Immuno Appoints Dr. Sonya as Chief Development Officer
13 Jan 2025 //
GLOBENEWSWIRE
OSE Immunotherapeutics to Present Lusvertikimab Ph 2 Result at ECCO
18 Dec 2024 //
GLOBENEWSWIRE
OSE Reports Positive Progress For Tedopi® Cancer Vaccine
11 Dec 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Strengthens Leadership And Executive Team
02 Dec 2024 //
GLOBENEWSWIRE
OSE Immuno Announces Positive Lusvertikimab UC Phase 2 Data
04 Nov 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presents New “Cis-Demasking” Technology
17 Oct 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Announces H1 2024 Results
26 Sep 2024 //
GLOBENEWSWIRE
OSE Immuno Launches Artemia Phase 3 Study for Cancer Vaccine
10 Sep 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports Positive Phase 2 Lusvertikimab Results
24 Jul 2024 //
GLOBENEWSWIRE
OSE Reports Symptom Improvements For Ulcerative Colitis Drug
24 Jul 2024 //
FIERCE BIOTECH
Boehringer and OSE to advance cancer immunotherapy to clinics
04 Jul 2024 //
PHARMACEUTICAL TECHNOLOGY
OSE Announces Publication of Preclinical Results with Lusvertikimab in Leukemia
01 Jul 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Enters Agreement With MSK For CAR T-Cell Therapies
25 Jun 2024 //
PHARMABIZ
OSE announces CAR T-cell therapy commercial and revenue sharing agreement.
24 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Presents MRNA Platform Data At FOCIS Annual Meeting
20 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports On 2024 Meeting And Board Evolution
19 Jun 2024 //
GLOBENEWSWIRE
OSE, Nantes: Positive Renal Transplant Immunotherapy Data
05 Jun 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Provides Business and Corporate Update
30 May 2024 //
GLOBENEWSWIRE
Boehringer And OSE Expand Collaboration For Cancer And Cardio-Renal Therapies
22 May 2024 //
PRESS RELEASE
OSE, Boehringer Expand Collaboration For Cancer, Cardio-Renal Treatments
22 May 2024 //
GLOBENEWSWIRE
Boehringer pays OSE $42M to grab new asset, expand into cardio
22 May 2024 //
FIERCE BIOTECH
OSE Immunotherapeutics Receives Public Funding for Tedopi® Trial
10 Apr 2024 //
GLOBENEWSWIRE
OSE Immunotherapeutics Reports Full Year 2023 Financial Results
27 Mar 2024 //
GLOBENEWSWIRE
